Menu

Pipeline Overview

Drug** Planned
Indication
Pre-clinical Phase i/ii Phase iii NDA/MAA
GI & Inflammation
RHB-105 H. pylori infections
RHB-104 Crohn's disease
Multiple sclerosis
BEKINDA®
(RHB-102)
Gastroenteritis & gastritis
IBS-D
RHB-106 Bowel cleanser
Oncology -
GI/Inflammation
YELIVA® (ABC294640) Multiple indications
MESUPRON Pancreatic Cancer
Other
RIZAPORT®
(RHB-103)
Migraine
*Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies ** BEKINDA®, YELIVA® and RIZAPORT® are proposed tradenames which are subject to FDA review and approval;

Company Profile

RedHill Biopharma (NASDAQ / TASE: RDHL) is a specialty biopharmaceutical company focused primarily on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

Read more